Advertisement

Topics

Bayer, Janssen halt phase III ESUS study of anticoagulant medicine Xarelto

03:22 EDT 9 Oct 2017 | Pharmaceutical Business Review

Bayer, along with its development partner Janssen Research & Development, has halted the phase III Navigate ESUS study of rivaroxaban (Xarelto), as it demonstrated comparable efficacy between treatment arms.

Original Article: Bayer, Janssen halt phase III ESUS study of anticoagulant medicine Xarelto

NEXT ARTICLE

More From BioPortfolio on "Bayer, Janssen halt phase III ESUS study of anticoagulant medicine Xarelto"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...